Posted by Michael Wonder on 28 Sep 2017
Stallergenes Greer advances its house dust mite allergy pipeline with acceptance of regulatory submission and new market approval
26 September 2017 - The company also received market approval to commercialise STG320 in New Zealand under the Actair brand name. The product is already available in Japan, Australia and South Korea.
Stallergenes Greer today announced that Health Canada accepted for review the company’s new drug submission for STG320, an investigational sublingual immunotherapy tablet for the treatment of house dust mite induced allergic rhinitis.
Once a new drug submission is accepted for review it takes usually between nine to twelve months for Health Canada to issue the results of the evaluation.
